Indinavir Sulfate(in din’ ah ver)
Crixivan
PREGNANCY CATEGORY C
Drug Classes
Antiretroviral
Antiviral
Protease inhibitor
Therapeutic Actions
Antiviral activity; inhibits HIV protease activity, leading to production of immature, noninfective HIV particles.
Indications
Treatment of HIV infection in adults; used in combination with other drugs
Contraindications and Cautions
Contraindicated with allergy to component of indinavir.
Use cautiously with pregnancy, hepatic or renal impairment, lactation.
Available Forms
Capsules—200, 400 mg
Dosages
Adults
800 mg PO every 8 hr. With delavirdine, 600 mg PO every 8 hr with delavirdine 400 mg tid; with didanosine, administer more than 1 hr apart on an empty stomach; with itraconazole,
600 mg PO every 8 hr with itraconazole 200 mg bid; with ketoconazole, 600 mg PO every 8 hr; with rifabutin, 1,000 mg PO every 8 hr, reduce rifabutin by 50%.
600 mg PO every 8 hr with itraconazole 200 mg bid; with ketoconazole, 600 mg PO every 8 hr; with rifabutin, 1,000 mg PO every 8 hr, reduce rifabutin by 50%.
Pediatric patients
Safety and efficacy not established in children younger than 12 yr.
Patients with hepatic impairment
600 mg PO every 8 hr with mild to moderate hepatic impairment.
Pharmacokinetics
Metabolism: Hepatic; T1/2: 3–4 hr
Distribution: Crosses placenta; enters breast milk; 60% bound to human plasma proteins
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
